menu
    • menu
    [{"orgOrder":0,"company":"Megalith Pharmaceuticals","sponsor":"Corbus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"CRB-701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Megalith Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Megalith Pharmaceuticals \/ Corbus Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Megalith Pharmaceuticals \/ Corbus Pharmaceuticals"},{"orgOrder":0,"company":"Megalith Pharmaceuticals","sponsor":"Radiance Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"RB-164","moa":"ROR1","graph1":"Oncology","graph2":"Phase I","graph3":"Megalith Pharmaceuticals","amount2":1.1699999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.1699999999999999,"dosageForm":"Undisclosed","sponsorNew":"Megalith Pharmaceuticals \/ Radiance Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Megalith Pharmaceuticals \/ Radiance Biopharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Megalith Pharmaceuticals

    Menu

    Megalith Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Megalith Pharmaceuticals

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Megalith Pharmaceuticals

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RB-164

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Radiance Biopharma

                            Deal Size : $1,165.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Radiance Biopharma Enters Exclusive License for ROR-1 Targeted Antibody Drug Conjugate

                            Details : Under the licensing agreement, Radiance will be responsible for the development and commercialization of SYS6005 (RB-164), a novel clinical stage ADC targeting ROR-1 for treating neoplasms.

                            Product Name : SYS6005

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $15.0 million

                            February 19, 2025

                            Lead Product(s) : RB-164

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Radiance Biopharma

                            Deal Size : $1,165.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Megalith Pharmaceuticals

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Megalith Pharmaceuticals

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CRB-701

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Corbus Pharmaceuticals

                            Deal Size : $692.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Corbus Pharmaceuticals Expands Oncology Pipeline with The Addition of A Clinical Stage Nectin-4 Targeting Anti...

                            Details : The agreement covers exclusive commercialization rights to CRB-701, a novel clinical stage antibody drug conjugate (ADC) targeting Nectin-4, in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom, an...

                            Product Name : CRB-701

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $7.5 million

                            February 13, 2023

                            Lead Product(s) : CRB-701

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Corbus Pharmaceuticals

                            Deal Size : $692.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth